Developing a Minimum Data Set for Calcium Disorders and Osteoporosis Records

Document Type : Original Article


1 Associate Professor of Endocrine.Department of Nursing and Midwifery, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Professor of Endocrinology.Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

4 Assistant Professor of public health, Department of public health, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


Background and Objective: Diagnosis and treatment of calcium disorders (hypocalcemia and hypercalcemia) and osteoporosis as the most important metabolic bone disease, are of great importance in internal medicine and endocrine diseases. There is no checklist of patient records for diagnosis, treatment and follow up in Iranian and foreign resources. This study was designed to provide minimum data set for registration in patient medical records.
Subjects and Methods: Using Iranian and foreign published literature, a preliminary data form was prepared and evaluated using Delphi technique. In first stage the opinions of 25 internal specialists and 25 endocrinologists who selected 75% or more as"high" for a data question were included as main element in record.  In the second stage, elements selected as "high" or "middle" (50-75 %) were assessed by 10 endocrinologist and analyzed.  Elements that had greater than or equal to 50% chose "high" were added to final checklist.
Results: Selected elements presented as checklist, and minimum data set in 7 categories: demographic information, history, symptoms, signs, paraclinical data, treatment and follow-up for disease presented. The scores for osteoporosis was 158 out of 187, while hypocalcemia was 82 of 140 and hypercalcema was 85 of 158.
Conclusion: These final elements provide as an applied pattern for registration in patients’ medical records and contain the most important elements in the published literature.


1-Karimi S, Saghaeiannejed IS, Farzandipour M, Esamaeili GM. Comparative study of minimum data sets of health nformation management of organ transplantation in selected countries and presenting appropriate solution for Iran. 2011
2-Wilczynski C, Camacho P. Calcium use in the management of osteoporosis: continuing questions and controversies. Current osteoporosis reports. 2014 Dec;12(4):396-402. PubMed PMID: 25228457. Epub 2014/09/18
3-Goff JP. Calcium and magnesium disorders. The Veterinary clinics of North America Food animal practice. 2014 Jul;30(2):359-81, vi. PubMed PMID: 24980727. Epub 2014/07/02
4-Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009 Jun 2;119(21):2765-71. PubMed PMID: 19451355. Epub 2009/05/20
5-Vestergaard P, Thomsen S. Medical treatment of primary, secondary, and tertiary hyperparathyroidism. Curr Drug Saf. 2011 Apr;6(2):108-13. PubMed PMID: 21524244. Epub 2011/04/29. Eng
6-Clarke BL. Bone disease in hypoparathyroidism. Arq Bras Endocrinol Metabol. 2014 Jul;58(5):545-52. PubMed PMID: 25166046. Epub 2014/08/29
7-Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet (London, England) 09;377(9773):1276-87. PubMed PMID: 21450337. Pubmed Central PMCID: PMC3555696. Epub 2011/04/01. Eng
8-Miller PD. Management of severe osteoporosis. Expert opinion on pharmacotherapy. 2016;17(4):473-88. PubMed PMID: 26605922. Epub 2015/11/26
9-Ahmadi M, Mohammadi A, Chraghbaigi R, Fathi T, Shojaee Baghini M. Developing a minimum data set of the information management system for orthopedic injuries in iran. Iran Red Crescent Med J. 2014 Jul;16(7):e17020
10-Silverman SL, Komm BS, Mirkin S. Use of FRAX(R)-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy. Maturitas. 2014 Nov;79(3):241-7. PubMed PMID: 25124532. Epub 2014
11-Greutelaers B, Kullen K, Kollias J, Bochner M, Roberts A, Wittert G, et al. Pasieka Illness Questionnaire: its value in primary hyperparathyroidism. ANZ J Surg. 2004 Mar;74(3):112-5. PubMed PMID: 14996155. Epub 2004/03/05.
12-Darabi M, Delpisheh A, Gholami Parizad E, Nematollahi M, Sharifian R. Designing the Minimum Data Set for Iranian Children’ Health Records. sjimu. 2016; 24 (1) :114-125
13-Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, et al. Management of Hypoparathyroidism: Summary Statement and Guidelines. The Journal of Clinical Endocrinology & Metabolism. 2016;101(6):2273-83
14-Shah KH, Bhat S, Shetty S, Umakanth S. Hypoparathyroidism in pregnancy. BMJ Case Rep. 2015;2015 16.Krysiak R, Handzlik-Orlik G, Kedzia A, Machnik G, Okopien B. [Hypoparathyroidism: the present state of art]. Wiad Lek. 2013;66(1):18-29
15-Maeda SS, Fortes EM, Oliveira UM, Borba VCZ, Lazaretti-Castro M. Hypoparathyroidism and pseudohypoparathyroidism. Arquivos Brasileiros de Endocrinologia & Metabologia. 2006;50:664-73.
16-Kobayahi T, Sugimoto T, Chihara K. Clinical and Biochemical Presentation of Primary Hyperparathyroidism in Kansai District of Japan. Endocrine Journal. 1997;44(4):595-601.
17-Chan AK, Duh Q-Y, Katz MH, Slperstein AE, Clark OH. Clinical Manifestations of Primary Hyperparathyroidism Before and After Parathyroidectomy A Case-Control Study. Annals of Surgery. 1995;222(3):402.